A Study of the Effect of Tocilizumab on Markers of Atherogenic Risk in Patients With Moderate to Severe Rheumatoid Arthritis

NCT00535782 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

132

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: Tocilizumab
DRUG: Placebo
DRUG: Methotrexate

Sponsor

Hoffmann-La Roche